|
Cannabis Agonist Reduces Non-Hodgkin Lymphoma Tumor Growth, says study |
|
|
|
|
Stockholm, Sweden: The administration of the cannabinoid agonist R(+)-MA halts the spread and growth of cancerous tumors in animals with non-Hodgkin lymphoma, according to preclinical data published in the February 2008 issue of the International Journal of Cancer. Investigators at the Karolinska Institute in Stockholm reported that mice treated with R(+)-MA experienced a 40 percent reduction in tumor weight.
"The anti-proliferative and proapoptotic (stimulated cell death) effects of cannabinoids make the endocannabinoid system a potential new therapeutic target for individualized therapy in lymphomas," authors concluded.
Earlier this year, the journal Cancer Research reported that the administration of cannabinoids halts the spread of a wide range of cancers, including prostate cancer, breast cancer, lung cancer, pancreatic cancer, and brain cancer.
NORML Deputy Director Paul Armentano has a review of pot's anti-cancer properties online at the Huffington Post. "Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation," International Journal of Cancer, September 2008
InterScience:
http://www3.interscience.wiley.com/journal/119818234/abstract?CRETRY=1&SRETRY=0
Molecular Cancer Therapeutics: http://mct.aacrjournals.org/cgi/content/abstract/6/11/2921
Oncogene: http://www.nature.com/onc/journal/v27/n3/abs/1210641a.html
American Assoc. for Cancer Research: http://cancerres.aacrjournals.org/cgi/content/abstract/66/13/6748
PubMed article: http://www.ncbi.nlm.nih.gov/pubmed/16804518
Huffington Post:
http://www.huffingtonpost.com/paul-armentano/what-your-government-know_b_108712.html |
